Retrospective analysis of the incidence and outcome of late acute and chronic graft-versus-host disease—an analysis from transplant centers across Europe

Langer, Ronja; Lelas, Antonela; Rittenschober, Michael; Piekarska, Agnieszka; Sadowska-Klasa, Alicja; Sabol, Ivan; Desnica, Lana; Greinix, Hildegard; Dickinson, Anne; Inngjerdingen, Marit; Lawitschka, Anita; Vrhovac, Radovan; Pulanic, Drazen; Güneş, Sibel; Klein, Stefan; Moritz Middeke, Jan; Grube, Matthias; Edinger, Matthias; Herr, Wolfgang; Wolff, Daniel (2024) Retrospective analysis of the incidence and outcome of late acute and chronic graft-versus-host disease—an analysis from transplant centers across Europe. Frontiers in Transplantation, 3 . ISSN 2813-2440

PDF - Published Version - article Available under License Creative Commons Attribution. Download (838kB)

Abstract

Introduction: Chronic graft-versus-host disease (cGvHD) is a serious late complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: This multicenter analysis determined the cumulative incidence (CI) of cGvHD and late acute GvHD (laGvHD) and its impact on transplantation-related mortality (TRM), relapse (R), and overall survival (OS) in 317 patients [296 adults, 21 pediatrics (<12 years of age)] who underwent their first allo-HSCT in 2017. Results: The CI of laGvHD was 10.5% in adults and 4.8% in pediatrics, and the CI of cGvHD was 43.0% in all adult transplant patients and 50.2% in the adult at-risk cohort at the study end. The onset of cGvHD was de novo in 42.0% of patients, quiescent in 52.1%, and progressive in 5.9%. In adults, prophylactic use of antithymocyte globulin or posttransplant cyclophosphamide was associated with a significantly lower incidence of cGvHD (28.7%) vs. standard prophylaxis with calcineurin inhibitors (30.6%) and methotrexate/mycophenolate mofetil (58.4%) (all p < 0.01). TRM was significantly higher in patients with aGvHD (31.8%) vs. cGvHD (12.6%) and no GvHD (6.3%) (all p = 0.0001). OS in the adult at-risk cohort was significantly higher in patients with cGvHD (78.9%) vs. without (66.2%; p = 0.0022; HR 0.48) due to a significantly lower relapse rate (cGvHD: 14.5%; without cGvHD: 27.2%; p = 0.00016, HR 0.41). OS was also significantly higher in patients with mild (80.0%) and moderate (79.2%) cGvHD vs. without cGvHD (66.2%), excluding severe cGvHD (72.7%) (all p = 0.0214). Discussion: The negative impact of severe cGvHD on OS suggests a focus on prevention of severe forms is warranted to improve survival and quality of life.

Item Type:	Article
Uncontrolled Keywords:	chronic graft-versus-host disease (cGvHD); acute GvHD; aGvHD; stem cell transplantation; bone marrow transplantation
Subjects:	INTERDISCIPLINARY AREAS OF KNOWLEDGE > Biotechnology in Biomedicine (natural science, biomedicine and healthcare, bioethics area
Divisions:	Division of Molecular Medicine
Depositing User:	Ivan Sabol
Date Deposited:	19 Jun 2024 12:11
URI:	http://fulir.irb.hr/id/eprint/8900
DOI:	10.3389/frtra.2024.1332181

Actions (login required)

View Item